These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 27678175)

  • 1. Application of Nanomedicine to the CNS Diseases.
    Carradori D; Gaudin A; Brambilla D; Andrieux K
    Int Rev Neurobiol; 2016; 130():73-113. PubMed ID: 27678175
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nanoparticle-Based Technology Approaches to the Management of Neurological Disorders.
    Sim TM; Tarini D; Dheen ST; Bay BH; Srinivasan DK
    Int J Mol Sci; 2020 Aug; 21(17):. PubMed ID: 32842530
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Harnessing nanomedicine for modulating microglial states in the central nervous system disorders: Challenges and opportunities.
    Li H; Guan M; Zhang NN; Wang Y; Liang T; Wu H; Wang C; Sun T; Liu S
    Biomed Pharmacother; 2024 Aug; 177():117011. PubMed ID: 38917758
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immune cells: potential carriers or agents for drug delivery to the central nervous system.
    Zhang SS; Li RQ; Chen Z; Wang XY; Dumont AS; Fan X
    Mil Med Res; 2024 Mar; 11(1):19. PubMed ID: 38549161
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Delivering the Promise of Gene Therapy with Nanomedicines in Treating Central Nervous System Diseases.
    Luo M; Lee LKC; Peng B; Choi CHJ; Tong WY; Voelcker NH
    Adv Sci (Weinh); 2022 Sep; 9(26):e2201740. PubMed ID: 35851766
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Carbon Dots: A Future Blood-Brain Barrier Penetrating Nanomedicine and Drug Nanocarrier.
    Zhang W; Sigdel G; Mintz KJ; Seven ES; Zhou Y; Wang C; Leblanc RM
    Int J Nanomedicine; 2021; 16():5003-5016. PubMed ID: 34326638
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Drug delivery systems, CNS protection, and the blood brain barrier.
    Upadhyay RK
    Biomed Res Int; 2014; 2014():869269. PubMed ID: 25136634
    [TBL] [Abstract][Full Text] [Related]  

  • 8. How Precise are Nanomedicines in Overcoming the Blood-Brain Barrier? A Comprehensive Review of the Literature.
    Mohapatra P; Gopikrishnan M; Doss C GP; Chandrasekaran N
    Int J Nanomedicine; 2024; 19():2441-2467. PubMed ID: 38482521
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Influence factors on and potential strategies to amplify receptor-mediated nanodrug delivery across the blood-brain barrier.
    Wei Y; Xia X; Li H; Gao H
    Expert Opin Drug Deliv; 2023; 20(12):1713-1730. PubMed ID: 37542516
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Brain Targeting Nanomedicines: Pitfalls and Promise.
    Kakinen A; Jiang Y; Davis TP; Teesalu T; Saarma M
    Int J Nanomedicine; 2024; 19():4857-4875. PubMed ID: 38828195
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Personalized nanomedicine for CNS diseases.
    Kaushik A; Jayant RD; Bhardwaj V; Nair M
    Drug Discov Today; 2018 May; 23(5):1007-1015. PubMed ID: 29155026
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Critical Review of the Use of Surfactant-Coated Nanoparticles in Nanomedicine and Food Nanotechnology.
    Miyazawa T; Itaya M; Burdeos GC; Nakagawa K; Miyazawa T
    Int J Nanomedicine; 2021; 16():3937-3999. PubMed ID: 34140768
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Leveraging the interplay of nanotechnology and neuroscience: Designing new avenues for treating central nervous system disorders.
    Smith ES; Porterfield JE; Kannan RM
    Adv Drug Deliv Rev; 2019 Aug; 148():181-203. PubMed ID: 30844410
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recent advances in nanomaterials for neural applications: opportunities and challenges.
    Sisubalan N; Shalini R; Ramya S; Sivamaruthi BS; Chaiyasut C
    Nanomedicine (Lond); 2023 Nov; 18(26):1979-1994. PubMed ID: 38078433
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nanogels as potential drug nanocarriers for CNS drug delivery.
    Vashist A; Kaushik A; Vashist A; Bala J; Nikkhah-Moshaie R; Sagar V; Nair M
    Drug Discov Today; 2018 Jul; 23(7):1436-1443. PubMed ID: 29775669
    [TBL] [Abstract][Full Text] [Related]  

  • 16. RNA therapies for CNS diseases.
    Di Francesco V; Chua AJ; Huang D; D'Souza A; Yang A; Bleier BS; Amiji MM
    Adv Drug Deliv Rev; 2024 May; 208():115283. PubMed ID: 38494152
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nanomedicine strategies for central nervous system (CNS) diseases.
    Nagri S; Rice O; Chen Y
    Front Biomater Sci; 2023; 2():. PubMed ID: 38938851
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CNS therapeutics: Immune cells break the barriers.
    Thai K; Prat A
    Sci Transl Med; 2023 Nov; 15(721):eadh1150. PubMed ID: 37939159
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intranasal delivery of stem cells labeled by nanoparticles in neurodegenerative disorders: Challenges and opportunities.
    Alizadeh R; Asghari A; Taghizadeh-Hesary F; Moradi S; Farhadi M; Mehdizadeh M; Simorgh S; Nourazarian A; Shademan B; Susanabadi A; Kamrava K
    Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2023; 15(6):e1915. PubMed ID: 37414546
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lipid-Based Nanomedicine for Alzheimer's Disease: A Comprehensive Review of Recent Advances.
    Dhankhar S; Garg N; Sharma H; Chauhan S; Saini M
    Pharm Nanotechnol; 2024 Jun; ():. PubMed ID: 38867523
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.